SUL-238
Parkinson's Disease (PD)
GEN İlaç ve Sağlık Ürünleri A.Ş.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
255 Active assets in the Parkinson's Disease (PD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safinamide Zambon SpA | Phase 4 | A |
Cvt-301 Acorda Therapeutics | Phase 3 | A |
Istradefylline Georgetown University | Phase 4 | BBB |
Tvp-1012 Guangzhou Henovcom Bioscience Co. Ltd. | Phase 4 | BBB |
Pardoprunox Abbott Products | Phase 3 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →